More recently, the effect of PARP inhibitors was also validated in HR-deficient cancers without BRCA1/2 GPVs, suggesting widespread use of PARP inhibitors for cancers caused by GPVs in other HR pathway genes [62,63]. The gene discussed is BRCA1; the disease is cancer.